KR102417686B1 - 치환된 비시클릭 헤테로시클릭 화합물 - Google Patents

치환된 비시클릭 헤테로시클릭 화합물 Download PDF

Info

Publication number
KR102417686B1
KR102417686B1 KR1020187033099A KR20187033099A KR102417686B1 KR 102417686 B1 KR102417686 B1 KR 102417686B1 KR 1020187033099 A KR1020187033099 A KR 1020187033099A KR 20187033099 A KR20187033099 A KR 20187033099A KR 102417686 B1 KR102417686 B1 KR 102417686B1
Authority
KR
South Korea
Prior art keywords
methyl
pyridinyl
oxo
dihydroisobenzofuran
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187033099A
Other languages
English (en)
Korean (ko)
Other versions
KR20180134999A (ko
Inventor
프라샨타 구나가
제레미 릭터
나브나트 드니아노바 야다브
마노란잔 판다
스리니바술루 고데시
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20180134999A publication Critical patent/KR20180134999A/ko
Application granted granted Critical
Publication of KR102417686B1 publication Critical patent/KR102417686B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/041,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020187033099A 2016-04-20 2017-04-19 치환된 비시클릭 헤테로시클릭 화합물 Active KR102417686B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325255P 2016-04-20 2016-04-20
US62/325,255 2016-04-20
PCT/US2017/028231 WO2017184662A1 (en) 2016-04-20 2017-04-19 Substituted bicyclic heterocyclic compounds

Publications (2)

Publication Number Publication Date
KR20180134999A KR20180134999A (ko) 2018-12-19
KR102417686B1 true KR102417686B1 (ko) 2022-07-07

Family

ID=59215932

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033099A Active KR102417686B1 (ko) 2016-04-20 2017-04-19 치환된 비시클릭 헤테로시클릭 화합물

Country Status (14)

Country Link
US (1) US10851108B2 (https=)
EP (1) EP3445762B1 (https=)
JP (1) JP6905993B2 (https=)
KR (1) KR102417686B1 (https=)
CN (1) CN109311874B (https=)
AU (1) AU2017252546B2 (https=)
BR (1) BR112018071548A2 (https=)
CA (1) CA3021335A1 (https=)
EA (1) EA037300B1 (https=)
ES (1) ES2962315T3 (https=)
IL (1) IL262448B (https=)
MX (1) MX381425B (https=)
SG (1) SG11201809173TA (https=)
WO (1) WO2017184662A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3535258B1 (en) * 2016-11-03 2021-11-24 Bristol-Myers Squibb Company Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors
HUE056142T2 (hu) 2017-06-01 2022-01-28 Bristol Myers Squibb Co Szubsztituált nitrogéntartalmú vegyületek
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
TW202527931A (zh) * 2023-11-08 2025-07-16 美商奧科坦特公司 視紫質的藥理校正劑及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039802A1 (en) 2011-09-16 2013-03-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014085210A1 (en) 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8824291D0 (en) 1988-10-17 1988-11-23 Zambeletti Spa L Novel use
DE102004020908A1 (de) 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
CA2624625A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
EA200900779A1 (ru) 2006-12-14 2010-02-26 Байер Шеринг Фарма Акциенгезельшафт Производные дигидропиридина, полезные как ингибиторы протеинкиназы
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8455522B2 (en) 2009-05-15 2013-06-04 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
EP2632465B1 (en) 2010-10-27 2015-12-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632464B1 (en) 2010-10-29 2015-04-29 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
MX2014001946A (es) 2011-08-19 2014-03-27 Merck Sharp & Dohme Inhibidores del canal de potasio medularmente externo renal.
WO2013026914A1 (en) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Serine/threonine pak1 inhibitors
WO2013062892A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062900A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773351B1 (en) 2011-10-31 2017-08-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773206B1 (en) 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2790511B1 (en) 2011-12-16 2016-09-14 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN104011050A (zh) 2011-12-22 2014-08-27 霍夫曼-拉罗奇有限公司 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物
WO2014015495A1 (en) 2012-07-26 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
JP6215338B2 (ja) 2012-11-08 2017-10-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
TWI692469B (zh) 2012-11-09 2020-05-01 南韓商Lg化學股份有限公司 Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
WO2014089324A1 (en) 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9604998B2 (en) 2013-02-18 2017-03-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014150132A1 (en) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP6103527B2 (ja) 2013-04-17 2017-03-29 矢崎総業株式会社 余長吸収装置及びコイルユニット
FR3008977A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015017305A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibitors of the renal outer medullary potassium channel
EP3063142B1 (en) 2013-10-31 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015095097A2 (en) * 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015096035A1 (en) * 2013-12-24 2015-07-02 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2015103756A1 (en) 2014-01-09 2015-07-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
BR112016029065A2 (pt) 2014-07-14 2017-08-22 Merck Sharp & Dohme ?composto, composição farmacêutica, e, uso de um composto?
WO2016008064A1 (en) * 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
EP3207030A4 (en) 2014-10-14 2018-06-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065582A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065602A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2016065603A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3212617A1 (en) 2014-10-31 2017-09-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN105980379B (zh) 2014-12-08 2018-09-07 江苏恒瑞医药股份有限公司 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用
CN105693706B (zh) 2014-12-10 2019-11-22 江苏恒瑞医药股份有限公司 异苯并呋喃酮类衍生物、其制备方法及其在医药上的应用
EP3250204B1 (en) 2015-01-29 2019-10-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039802A1 (en) 2011-09-16 2013-03-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014085210A1 (en) 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel

Also Published As

Publication number Publication date
IL262448A (en) 2018-12-31
IL262448B (en) 2020-08-31
JP2019515911A (ja) 2019-06-13
EP3445762B1 (en) 2023-09-13
EA201892382A1 (ru) 2019-03-29
MX2018012840A (es) 2019-03-11
AU2017252546A1 (en) 2018-12-06
US10851108B2 (en) 2020-12-01
CN109311874A (zh) 2019-02-05
WO2017184662A1 (en) 2017-10-26
MX381425B (es) 2025-03-12
BR112018071548A2 (pt) 2019-04-16
EP3445762A1 (en) 2019-02-27
ES2962315T3 (es) 2024-03-18
SG11201809173TA (en) 2018-11-29
CN109311874B (zh) 2021-07-30
US20190127380A1 (en) 2019-05-02
KR20180134999A (ko) 2018-12-19
EA037300B1 (ru) 2021-03-05
AU2017252546B2 (en) 2021-07-29
JP6905993B2 (ja) 2021-07-21
CA3021335A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
KR102849449B1 (ko) 치환된 인돌 화합물
WO2021219072A1 (zh) 作为kras抑制剂的杂环化合物的制备及其应用方法
CA3103976A1 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
KR101875238B1 (ko) 포스포디에스테라아제 (pdes) 저해제로서의 융합 헤테로시클릭 화합물
JP2021528466A (ja) ハンチントン病を処置するためのヘテロアリール化合物
AU2018393003A1 (en) Aryl and heteroaryl substituted indole compounds
WO2018005586A1 (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
KR20230019431A (ko) Enpp1의 이미노 설파논 억제제
KR102417686B1 (ko) 치환된 비시클릭 헤테로시클릭 화합물
TW202115061A (zh) 一類具有brd4抑制活性的化合物、其製備方法及用途
EP3271362B1 (en) Heterocyclic compounds useful as inhibitors of tnf
TW202214233A (zh) 可做為tlr9抑制劑之經取代雜芳基化合物
TW202321247A (zh) 用於治療杭丁頓氏舞蹈症的雜芳基化合物
CA3185649A1 (en) Indole compounds as androgen receptor modulators
TW202339721A (zh) Bcl-xL抑制劑
CN112300154B (zh) 一类含氮杂环化合物、其制备方法和用途
IL298397A (en) Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor m5
CA3029620C (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CA3249905A1 (en) Substituted bicyclic heteroaryl compounds useful as TLR9 inhibitors
CA3249560A1 (en) USEFUL IMIDAZOPYRIDINYL COMPOUNDS AS TLR9 INHIBITORS

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200420

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211018

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220404

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220701

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220701

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250616

Start annual number: 4

End annual number: 4